Recombinant human interleukin-7

Phase 2Protein / enzyme

NNational Institute of Allergy and Infectious Diseases (NIAID)

Recombinant human interleukin-7 is one of 6 small molecule programs targeting Lymphopenia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphopeniaRecruiting

LymphopeniaPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Lymphopenia

#DrugCompanyPhaseTrials

Mozobil

GGenzyme, a Sanofi Company

Approved

—2

Benlysta

GGlaxo Dba Glaxosmithkline

Phase 1

1 3

Tecfidera

Biogen

Preclinical

1 4

Recombinant human interleukin-7

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

1 5

Nicotinamide

MMetro International Biotech, LLC

Preclinical

1 6

Nogapendekin Alfa Inbakicept

IImmunityBio, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Lymphopenia

NCT05600920

Clinical

Trials by Indication[1]

4 more indications

Immunogenicity1 trial

Anthrax-rPA: Safety, Tolerability, Immunogenicity

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00063843·80 enrolled

Adjuvant1 trial

Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01376765

Lung Disease1 trial

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease

Terminated·RRevimmune·Phase 2·NCT04154826·8 enrolled

Lymphopenia1 trial

An Open-Label, Single-Arm, Phase 1/2 Dose-Escalation Trial of Long-Acting Recombinant Human IL-7 (NT-I7, Efineptakin-Alpha) for Idiopathic CD4 Lymphopenia

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT05600920·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Recombinant human interleukin-7. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant human interleukin-7 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant human interleukin-7. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Recombinant human interleukin-7

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Interleukin1 trial

Asthma1 trial

Transgender Persons1 trial

Adult1 trial

Single Dose1 trial

Immunogenicity1 trial

Adjuvant1 trial

Lung Disease1 trial

Lymphopenia1 trial

References

Drug Info

Quick Facts

Related News